VP Immuno-Oncology @ (October 2016 - January 2020)
VP Immunotherapy and Drug Conjugates @ (January 2015 - September 2016)
VP Immunotherapy and Antibody-Drug Conjugates @ (September 2011 - December 2014)
Head of Department Targeted Biological Therapeutics @ (March 2009 - August 2011)
Group Leader Functional Genomics @ Schering AG / Bayer HealthCare (January 2005 - February 2009)
Research Scientist @ Schering AG (November 1999 - December 2004)
Bertolt Kreft Education
The University of North Carolina at Chapel Hill
Postdoctoral fellow in Cell Biology
1997-1999
Freie Universität Berlin
Dr. rer. nat. (Biochemistry)
1992-1997
Freie Universität Berlin
Diploma (Biochemistry)
1986-1992
Bertolt Kreft Skills
Oncology Research
Preclinical Drug Development
Pharmaceutical Industry
Antibody-Drug Conjugates
Antibody-based cancer therapeutics
Project Portfolio Management
Cross-functional Team Leadership
Head of Department
Licensing Negotiations
Arzneimittelentwicklung
Pharmaindustrie
Onkologie
Lizenzierung
Portfoliomanagement
Abteilungsübergreifende Teamführung
Biochemie
Biotechnologie
Immuno-Oncology
Customer Service
Project Portfolio
Preclinical Drug
Antibody Based Cancer Therapeutics
Business Development
Sales
Antibody Drug Conjugates
Antibody Based Cancer
Management
Biochemistry
Cross Functional Team Leadership
Cross Functional Team
Molecular Biology
Immuno Oncology
Bertolt Kreft Summary
Bertolt Kreft, based in Basel, BS, CH, is currently a Chief Scientific Officer at Bright Peak Therapeutics at Bright Peak Therapeutics. Bertolt Kreft brings experience from previous roles at Bayer Pharmaceuticals. Bertolt Kreft holds a 1997 - 1999 Postdoctoral fellow in Cell Biology @ The University of North Carolina at Chapel Hill. With a robust skill set that includes Oncology Research, Preclinical Drug Development, Pharmaceutical Industry, Antibody-Drug Conjugates, Antibody-based cancer therapeutics and more. Bertolt Kreft has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Bertolt Kreft?
Find contact details for 700 million professionals.